Orek

Quick links to important sections

Orek

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Orek

Property Description
Active ingredient Alendronate sodium (Alendronic acid)
Form Oral tablet, Oral solution, Effervescent tablet
Pharmacological class Bisphosphonate (Nitrogen-containing)
General purpose Bone density conservation / Antiresorptive agent
Origin Synthetic analog of pyrophosphate

Orek is a synthetic compound medication containing the active chemical Alendronate sodium, which belongs to the major drug class known as bisphosphonates. Specifically, it is categorized as a nitrogen-containing bisphosphonate (N-BP), distinguishing it within this family of agents that regulate bone structure. The medicine is characterized as a single-active ingredient product, deriving its therapeutic effects solely from the potent action of the Alendronate compound. Being a synthetic analog of natural pyrophosphate, Alendronate was engineered to specifically target mineralized bone tissue. The substance is clinically recognized for its high affinity for bone mineral.

The medication is primarily taken via the oral route of administration and is available in common dosage form(s), including the standard oral tablet and the oral solution, as well as an effervescent tablet formulation designed for dissolution prior to ingestion. The active component, Alendronate sodium trihydrate, is entirely synthetic in origin. Its form as an oral medication is structured to resist the highly acidic conditions of the stomach, enabling it to be absorbed and transported effectively to the skeleton.

The overall general purpose of Orek is to function as a bone density conservation agent by significantly slowing down the process of natural bone loss. The medication achieves this by exerting an antiresorptive effect, which means it targets and neutralizes the activity of specialized cells called osteoclasts that are responsible for breaking down old bone material. Alendronate acts as a potent inhibitor of osteoclast-mediated bone resorption. By inhibiting this osteoclast-mediated bone resorption, Orek helps to stabilize the bone structure, which is fundamental for enhancing and maintaining overall bone mineral density (BMD), a typical goal when managing conditions characterized by skeletal weakening.

Regulatory References

  1. Alendronate - NCBI Bookshelf

What side effects are possible with Orek?

Possible Side Effects and Safety Information

Orek (Alendronate sodium), like all medicines, has an official safety profile documented by regulatory authorities. Adverse reactions are classified by system-organ classes and by frequency of occurrence.

Adverse Reaction Categories and Frequency

The most commonly reported side effects generally involve the gastrointestinal system and the musculoskeletal system.

Classification Examples of Reactions
Common Headache, abdominal pain, indigestion (dyspepsia), constipation, diarrhea, flatulence, and musculoskeletal pain (bone, muscle, or joint).
Uncommon Nausea, vomiting, gastritis, oesophagitis, oesophageal erosions, rash, and pruritus (itching).

Serious Adverse Reactions

Official labeling documents certain serious adverse reactions that are considered rare but clinically significant. These include severe upper gastrointestinal events such as oesophageal ulceration, bleeding, or stricture. Other rare, serious risks pertain to bone health, specifically osteonecrosis of the jaw (ONJ), which is localized bone death, and atypical femoral fractures (fractures of the subtrochanteric and femoral shaft).

Population-Specific and Time-Related Safety Notes

The medication is formally contraindicated in individuals with severe renal impairment, typically defined as a creatinine clearance of less than 35 ml/min. Additionally, it is restricted for patients who have pre-existing abnormalities of the oesophagus or who are unable to remain sitting or standing upright for at least 30 minutes. Transient, flu-like symptoms (e.g., malaise, fever) are sometimes reported shortly after treatment initiation, while serious bone-related effects (ONJ, atypical fractures) are primarily associated with prolonged use.

This regulatory safety structure highlights common, often manageable, digestive and pain-related events alongside rare, severe risks requiring long-term observation, particularly in patients with pre-existing kidney or oesophageal limitations.

Overdose and Emergency Response

Overdose and When to Seek Help

This section describes the officially documented manifestations of overdose with alendronate sodium (Orek) and the required emergency actions as stated in government regulatory labeling.


Documented Overdose Manifestations

Acute overdose may lead to clinical findings reflecting both its local irritant effect and its impact on mineral metabolism. These documented manifestations include:

  • Upper Gastrointestinal Adverse Reactions: Upset stomach (dyspepsia), heartburn, esophagitis, gastritis, or ulcers.
  • Metabolic Abnormalities: Hypocalcemia (low calcium levels in the blood) and hypophosphatemia (low phosphate levels in the blood).

Required Emergency Actions

If an overdose is suspected, the regulatory information mandates specific, immediate actions:

  • Mandatory Help-Seeking: The patient must contact the local poison control center or emergency room right away.
  • Prevent Further Absorption: Administration of milk or antacids is required to bind the alendronate and minimize its absorption.
  • Avoid Vomiting: Vomiting must not be induced due to the risk of severe esophageal irritation. The patient should remain in a fully upright position.

Management and Antidote Status

Management of overdose is primarily symptomatic and supportive treatment. No specific antidote is known for alendronate overdose. Corrective measures may include administering intravenous calcium to address documented hypocalcemia and monitoring serum calcium and phosphate levels.

Therapeutic Uses of Orek

Therapeutic Indications and Mechanism

Orek is an antipsychotic medication primarily utilized for the management of schizophrenia and as an adjunctive treatment for major depressive disorder. It belongs to the class of medications known as atypical antipsychotics, which work by modulating the activity of specific neurotransmitters in the brain, notably dopamine and serotonin.

Schizophrenia

In the treatment of schizophrenia, the medication is used to address both positive and negative symptoms of the condition. By stabilizing dopamine signaling, it helps to mitigate symptoms such as:

  • Hallucinations: Sensory experiences, such as hearing voices, that occur without external stimuli.
  • Delusions: Strongly held false beliefs that are not grounded in reality.
  • Disorganized thinking: Difficulties in maintaining a coherent train of thought or speech.

Major Depressive Disorder (MDD)

Orek is also indicated as an add-on therapy for adults with major depressive disorder who have not achieved an adequate response to antidepressant monotherapy. In this context, it is not used as a standalone treatment but rather to enhance the effectiveness of existing antidepressant regimens. The goal of this combined approach is to further alleviate persistent symptoms of low mood, loss of interest, and fatigue.

Potential Benefits and Clinical Impact

The primary objective of treatment with Orek is the stabilization of mood and cognitive function. When integrated into a comprehensive care plan, the benefits may include:

  • Reduction in Symptom Severity: Lowering the frequency and intensity of acute psychotic or depressive episodes.
  • Improved Cognitive Clarity: Enhancing the ability to process information and maintain focus on daily tasks.
  • Support for Social Functioning: By managing symptoms, the medication can assist individuals in maintaining interpersonal relationships and participating in social or professional activities.
  • Prevention of Relapse: Long-term use is often aimed at maintaining symptom remission and reducing the likelihood of future hospitalizations or acute setbacks.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Orek (Alendronate sodium) eligibility is strictly defined by government regulatory agencies based on specific population and health status criteria.

Official Eligibility and Non-Eligibility Status

Eligibility Status Patient Condition
Contraindicated (Must Not Use) Known hypersensitivity to the drug, active hypocalcemia (low blood calcium), or esophageal abnormalities (e.g., stricture or achalasia) that delay emptying. Use is also prohibited if the patient is unable to stand or sit upright for at least 30 minutes after administration.
Not Recommended Patients with severe renal impairment where Creatinine Clearance is below 35 mL/min. Use is also not recommended for the pediatric population (under 18 years) due to insufficient efficacy and safety data.

Orek is generally permitted for use in adults and older adults with the established regulatory indications, and no dosage adjustment is necessary for patients with hepatic impairment. However, use requires caution in patients with active upper gastrointestinal diseases, such as ulcers or gastritis. Furthermore, use is generally not recommended during pregnancy, and nutritional deficiencies like inadequate calcium and Vitamin D must be corrected before treatment begins.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Clinical study data indicates that Orek has the potential for interactions that may affect how other medicines work or change the concentration of Orek in the body. The majority of these interactions involve specific enzyme systems in the liver responsible for drug metabolism, primarily the Cytochrome P450 (CYP) enzymes, or drug transport proteins.


Interacting Medicinal Products and Classes

Interaction Classification Interacting Agents or Classes
Contraindicated Strong CYP3A4 inducers (e.g., rifampicin)
Use with Caution Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin), P-glycoprotein inhibitors (e.g., ciclosporin)
Requires Spacing Medicines that rely on gastric pH for absorption (e.g., certain antifungals)

Co-administration with strong inhibitors of CYP3A4, the main enzyme involved in Orek's metabolism, may significantly increase the plasma levels of Orek, leading to an elevated potential for side effects. Conversely, concurrent use of strong CYP3A4 inducers is known to rapidly decrease Orek concentrations, potentially reducing its effectiveness. Due to the risk of therapeutic failure, co-administration with strong inducers is generally restricted.

Patients should inform their healthcare provider about all prescription and non-prescription medicines, herbal products, and dietary supplements being used. This includes products that may impact stomach acidity or affect the CYP enzyme pathways, even if they are not listed above, to ensure safe use and appropriate management.

Mechanism of Action

Orek (Alendronate) produces a concentrated and localized anti-resorptive effect by disrupting the fundamental metabolic pathways of the bone-dissolving cells. The molecule exhibits a high chemical affinity for the hydroxyapatite crystals on the bone surface, ensuring it is delivered precisely to areas undergoing active remodeling. Once internalized by the osteoclast, Orek competitively inhibits the enzyme Farnesyl Pyrophosphate Synthase (FPPS) within the mevalonate pathway. This molecular blockade prevents the cell from producing essential isoprenoid lipids, which are required for the prenylation of small GTPase signaling proteins. This failure to prenylate causes the osteoclast's internal structure (cytoskeleton) to collapse, leading to the loss of functional integrity. This cellular failure culminates in apoptosis (programmed cell death), which produces the core physiological change of reducing the rate of bone resorption. This mechanism modulates the balance of the bone remodeling cycle by suppressing osteoclast activity.

Dosage and Administration Information

Orek is administered exclusively by the oral route and is available in formulations including the standard oral tablet, oral solution, and effervescent tablet. The general frequency pattern is either once daily (5 mg, 10 mg, or 40 mg) or once weekly (35 mg or 70 mg).

To ensure proper absorption, the medication must be taken immediately upon arising for the day, utilizing a full glass (at least 200 mL) of plain water only. It must be consumed a minimum of 30 minutes before the first food, beverage, or other oral medication of the day. Liquids other than plain water are avoided, as they interfere with the absorption of the active compound.

After taking the dose, the patient must remain fully upright (sitting, standing, or walking) for at least 30 minutes and until after consuming the day’s first meal. Tablets must be swallowed whole; they should not be crushed, chewed, or allowed to dissolve in the mouth. In the event of a missed dose, the standard procedure is to skip the missed daily dose; however, a missed weekly dose is taken the morning after it is remembered, ensuring no two doses are taken on the same day.

Usage guidelines for specific populations indicate that no dosage adjustment is required for older adults. However, the medicine is not recommended for use in patients with severe renal impairment, defined as a creatinine clearance (CrCl) less than 35 mL/min.

Recent Clinical Evidence

Research evidence / Overview of studies for Orek

Research primarily evaluated Orek in studies of bone density. The research includes large-scale clinical trials and long-term studies that monitor its patterns of use and observed changes across approved patient groups. Research examined outcomes related to skeletal health, including fracture incidence and changes in bone mineral density (BMD). The findings describe group patterns and contribute to the broader evidence landscape, but research does not determine whether an individual will respond similarly.


Evidence for Use in Postmenopausal Osteoporosis

Research explored the use of Orek in postmenopausal women through multiple large, placebo-controlled Randomized Controlled Trials (RCTs) and open-label, long-term extension studies. Studies examined the occurrence of new fractures, specifically at the hip, spine (vertebral fractures), and other major sites, and monitored BMD measurements.

Studies monitored the incidence of fractures. Findings describe patterns observed in the studies related to the rate of vertebral and hip fractures in the Orek groups compared to the placebo groups. Studies reported measurements of BMD that evolved in the observed populations over defined time intervals.


Evidence for Other Approved Bone Conditions

Research has explored Orek in various approved conditions associated with skeletal fragility.

Research for Osteoporosis in Men

Research examined adult men diagnosed with osteoporosis. The studies primarily examined changes in BMD in the spine and hip. Findings describe patterns observed in the studies related to changes in BMD measured during the study period.

Research for Paget’s Disease of Bone

Orek was evaluated in studies focused on conditions involving periods of heightened symptoms, such as Paget’s Disease of Bone. Research describes patterns observed in the studies related to the suppression of bone turnover markers, with measured levels often evolving toward the normal range within a year.


What Research Gaps and Uncertainties Remain

Research is ongoing to explore the optimal duration of administration beyond five years and the effects of pausing treatment. Research exploring the overall rate of fracture incidence is not fully established beyond the intermediate-term follow-up of the main trials, and data are still emerging. Evidence related to the medication's effect on overall survival across all causes was associated with mixed findings in some systematic reviews.

Frequently Asked Questions (FAQ)

Common questions about Orek (FAQ)


Q: Is Orek considered a first-line treatment for its primary indication?

Authoritative regulatory documents often describe the class of medicine Orek belongs to, bisphosphonates, as a first-line treatment of choice for most patients with postmenopausal osteoporosis. This classification is based on robust research evidence regarding its effectiveness in reducing the risk of fracture.

Q: Does Orek work the same way for everyone who takes it?

Official research evidence describes the patterns observed in studies across large groups of patients. While the drug's mechanism of action is consistent, regulatory documents do not determine how any individual person will respond. Clinical trials often report a range of individual outcomes regarding changes in bone mineral density, indicating variability.

Q: How often do people experience serious side effects with Orek?

Official labeling documents classify serious side effects, such as osteonecrosis of the jaw (ONJ) and atypical femoral fractures, as rare events. The most frequently reported adverse reactions generally involve the gastrointestinal system and the musculoskeletal system. The complete safety profile is documented in the official product information.

Q: Does Orek interact with common over-the-counter pain relievers?

Official information, including guidance from the NIH, advises caution with co-administration of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs), which are common OTC pain relievers. This is associated with a potential for increased upper gastrointestinal side effects when these are used concurrently.

Q: Is there a known interaction between Orek and alcohol?

Regulatory documents indicate that consuming alcohol may raise the risk of certain digestive side effects, such as irritation or ulcers in the esophagus. There is no direct chemical interaction with the drug itself mentioned in official labeling.

Q: How long does it usually take before Orek starts to have an effect?

The medicine's action on bone begins relatively quickly. The reduction in bone breakdown (resorption) is evident through biochemical changes as early as one month after starting treatment. However, the full therapeutic effect, such as the stabilizing of bone mineral density, typically develops over three to six months.

Q: How long does one dose of Orek last in the body?

Once Orek is absorbed into the bloodstream, it rapidly binds to the bone surface. Because of this strong binding affinity, the drug is slowly released from the skeleton, and its estimated terminal half-life in the body is reported to exceed 10 years.

Q: Is Orek safe to use during pregnancy?

Official prescribing information indicates the medicine is generally not recommended for use during pregnancy. Documents state it should be avoided because its mechanism of action could potentially cause skeletal-related risks to the fetus, based on findings from non-human studies.

Q: Is Orek safe to use while breastfeeding?

Regulatory documents state that it is not known if Orek is secreted into human milk. The official documentation states that a decision to stop nursing or stop the medicine must be made, taking into account the drug's benefit to the patient, as it is unknown if the drug is excreted in human milk.

Q: Is there a generic version of Orek available?

Yes. The active compound in Orek is Alendronate sodium, and the FDA has approved generic versions of the drug for the standard oral tablet formulation.

Q: Why do some people need to take Orek with food?

Official instructions specify strict timing due to absorption requirements. The drug must be taken at least 30 minutes before any food or beverage (other than plain water). Taking it with food can significantly reduce the drug's absorption by up to 60%, potentially diminishing its effectiveness.

Q: Is Orek a medication that is known to be habit-forming?

Regulatory documents classify Orek as a drug not associated with abuse potential. It is not known to be habit-forming and does not cause dependence or withdrawal symptoms.

Q: What should I do if my Orek pills look slightly different than before?

The appearance of the medicine may change if the patient switches between the original brand and a generic version, or if the manufacturer modifies the formulation. If a change in appearance is noted, it is consistent with compliance guidelines to verify the drug's identity with a pharmacist to ensure it matches the authorized description.

Q: Can Orek cause changes in mood or sleep patterns?

Mood changes or sleep disturbances are not listed as common side effects in the main clinical trial data. However, symptoms such as depression and anxiety have been examined in post-marketing reports and are tracked by regulatory surveillance systems. Such symptoms, if experienced, are typically reviewed by a healthcare provider for determination.

Q: Can Orek be split or crushed if someone has trouble swallowing pills?

No. Official administration instructions state that tablets must be swallowed whole. They should not be crushed, chewed, or allowed to dissolve in the mouth due to the potential risk of causing irritation or ulceration in the upper gastrointestinal tract.

Q: Do patients typically feel different immediately after taking Orek?

The drug’s main effect on bone is not typically felt immediately. The most important immediate action is following the strict administration instructions to prevent irritation. Some individuals may report transient, flu-like symptoms (such as a general feeling of discomfort) shortly after the very first dose.

Q: Does Orek interact with common medications for high blood pressure?

There is no general contraindication with the entire class of blood pressure medicines listed in the official documents. Direct interference is unlikely, as Orek's metabolism is separate from the enzyme systems typically involved in drug-drug interactions. As with any medication, the use of Orek is managed by a healthcare provider who reviews all concurrent medications.

Q: Is a headache a normal side effect when starting Orek?

Yes, headache is listed in regulatory documents as a Common side effect. This means it was among the more frequently reported adverse reactions observed during the controlled clinical trials.

Q: Do the common side effects of Orek typically go away over time?

Official safety documents indicate that a type of side effect known as transient, flu-like symptoms are sometimes reported shortly after starting treatment and usually resolve quickly. For other common side effects, such as stomach upset, the likelihood of them lessening with continued use is not specifically detailed, but may be possible.

Q: What are the signs of a possible allergic reaction to Orek?

Official warnings note that a known hypersensitivity to the drug is a contraindication. Symptoms of a severe allergic reaction that have been reported include hives, swelling of the face, lips, tongue, or throat (angioedema), which could potentially cause difficulty breathing, and severe skin reactions.

Q: Is it safe to consume caffeine while taking Orek?

Liquids other than plain water, including those containing caffeine such as coffee or tea, must not be consumed for at least 30 minutes after taking the drug. Studies show that co-administration with coffee can significantly reduce the medicine's absorption, potentially reducing its effectiveness.

Q: Can Orek affect the way birth control pills work?

The drug's metabolism is not heavily reliant on the main liver enzyme systems typically involved in interactions with hormonal contraceptives. Because of this, there is no specific interaction with birth control pills listed in the official labeling. As with any medication, the use of Orek is managed by a healthcare provider who reviews all concurrent medications.

Q: What happens if Orek is taken by someone who does not have the condition it treats?

Regulatory documents do not detail the outcome of non-indicated use in a healthy individual. However, the risk of side effects, particularly gastrointestinal irritation and hypocalcemia (low blood calcium), is present for anyone taking the medicine, regardless of their underlying condition.

Q: Why does the packaging for Orek list so many precautions?

The comprehensive list of precautions is required by regulatory bodies because the drug is associated with a range of potentially serious, though rare, adverse events, including severe upper gastrointestinal irritation and bone-related risks like osteonecrosis of the jaw. The detailed warnings emphasize the critical importance of patient compliance with administration instructions to minimize risk.

Q: Is it normal to feel tired after starting Orek?

While tiredness (asthenia) is not listed as a common side effect, official documents do note malaise (a general feeling of discomfort or illness) as one of the transient, flu-like symptoms that is sometimes reported shortly after starting treatment. Such symptoms, if experienced and persistent, are typically reviewed by a healthcare provider.

Q: Are there certain foods or drinks mentioned in official documents that should be avoided with Orek?

Yes. Official documents specifically caution that liquids other than plain water, including coffee, tea, orange juice, and mineral water, should be avoided for at least 30 minutes after taking the dose, as they can significantly reduce the absorption and effectiveness of the medicine.

How should Orek be stored and disposed of?

How to Store and Dispose of Orek

The official regulatory labeling specifies precise conditions to maintain the stability and safety of Orek (Alendronate sodium).

Storage Conditions

Requirement Official Instruction
Temperature Store at controlled room temperature, 20 C to 25 C (68 F to 77 F). Do not allow the product to freeze and keep it away from excessive heat.
Protection Keep the medicine protected from both light and moisture.
Container Keep the product in its original, tightly closed, light-resistant container. Effervescent tablets must remain in their original blister packaging until use.
Child Safety Keep all medicines out of the reach of children and sight.

Disposal Instructions

All expired or unused Orek must be discarded. The regulatory mandate is to consult with a pharmacist or healthcare professional on the proper disposal procedures, ensuring compliance with local and national regulations for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Orek found in:

A-Z Index: